Cogent Biosciences

1. CGT4859 3 Inhibitor interim2026CGT4859 3 Inhibitor interim, 2026, notable
2. CGT1815 pan-KRAS Inhibitor IND filing2026CGT1815 pan-KRAS Inhibitor IND filing, 2026, notable
3. CGT1145 IND filing2026CGT1145 IND filing, 2026, notable
4. Bezuclastinib commercial launch2H 2026Bezuclastinib commercial launch, 2H 2026, routine
5. Bezuclastinib SUMMIT pivotal readoutBy end of 2026Bezuclastinib SUMMIT pivotal readout, By end of 2026, notable
6. Bezuclastinib NonAdvSM PDUFA dateDec 30, 2026Bezuclastinib NonAdvSM PDUFA date, Dec 30, 2026, thesis-defining
7. 1L exon 9 GIST extension20271L exon 9 GIST extension, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.